Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 478 results found since Jan 2013.

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices
AbstractAtrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran (a direct thrombin inhibitor) and apixaban, edoxaban, and rivaroxaban (factor Xa inhibitors) are not only non-inferior or superior to warfarin but also demonstrate a decreased risk of cerebrovascular bleeding among patients with AF and moderate to high risk of stroke. Additionally, NOACs have an adva...
Source: Cardiology and Therapy - February 27, 2018 Category: Cardiology Source Type: research

Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)
Conclusion MANAGE is the first randomized controlled trial to evaluate a potential treatment of patients who suffered MINS.
Source: Canadian Journal of Cardiology - February 3, 2018 Category: Cardiology Source Type: research

Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
CONCLUSIONS: Non-persistence (treatment discontinuation or switch) with vitamin K antagonists was lower than with rivaroxaban and dabigatran in French primary care; however, non-persistence with the newest drug, apixaban, was similar to vitamin K antagonists. Larger studies with longer follow-up are needed to support these findings. This study is registered on ClinicalTrials.gov (NCT02488421). PMID: 29398546 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefèvre C, Maguire A, Asmar J, Bizouard G, Duhot D, Mouquet F, Fauchier L Tags: Arch Cardiovasc Dis Source Type: research

Comparison of anticoagulant therapy for atrial fibrillation - novel oral anticoagulants versus vitamin K antagonists
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have historically been the standard of care, these medications are limited by numerous food and drug interactions with onerous requirements for frequent monitoring and dose adjustments. Over the past decade, several novel oral anticoagulants (NOACs) have been developed to directly inhibit factor IIa/thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, edoxaban).
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Sean T. Chen, Manesh R. Patel Source Type: research

Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have historically been the standard of care, these medications are limited by numerous food and drug interactions with onerous requirements for frequent monitoring and dose adjustments. Over the past decade, several novel oral anticoagulants (NOACs) have been developed to directly inhibit factor IIa/thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, edoxaban).
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Sean T. Chen, Manesh R. Patel Source Type: research

Efficacy and Safety of Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time – A RE-LY trial analysis
Conclusions In AF, WRF was associated with a higher risk of death and major bleeding. The efficacy and safety profile of dabigatran compared to warfarin was similar irrespective of renal function changes over time. Dabigatran 110 mg showed a greater relative risk reduction of major bleeding in patients with normal renal function during follow-up.
Source: American Heart Journal - January 6, 2018 Category: Cardiology Source Type: research

Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?
Authors: Bahrmann P, Christ M Abstract Based on established risk scores, such as the CHA2DS2-VASc score, the indications for oral anticoagulation are given for patients over 65 years old with atrial fibrillation and even more so for patients over 75 years old. Before beginning anticoagulation a geriatric assessment for evaluation of the cognitive ability, the activities of daily living and the risk of falling should be made because of the known complications of anticoagulation. Geriatric patients with non-valvular atrial fibrillation (AF) are increasingly being treated with non-vitamin K antagonist oral anticoagul...
Source: Herz - December 22, 2017 Category: Cardiology Tags: Herz Source Type: research

Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.
Authors: Joung B Abstract Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the...
Source: Korean Circulation Journal - November 26, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
Authors: Benedetti G, Neccia M, Agati L Abstract Non-valvular atrial fibrillation (NVAF) increases the risk of stroke by three- to five-fold, especially in elderly patients, creating a huge burden on medical system as well as a negative impact on patients lives. Balancing efficacy and bleeding risk is a challenge when considering anticoagulation therapy in elderly patients, because of their frequent high risk of both stroke and bleeding. Real world data reveal the underuse of anticoagulation in the elderly, especially due to physicians' fear of bleeding, often neglecting the thromboembolic risk. Care of elderly pat...
Source: Minerva Cardioangiologica - November 12, 2017 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
Conclusions PPI administration significantly decreased the trough and peak DCs in patients with NVAF. Therefore, when prescribing PPIs for patients with NVAF in a clinical setting, the possibility that the bioavailability of dabigatran may decrease should be considered.
Source: Journal of Arrhythmia - October 13, 2017 Category: Cardiology Source Type: research

Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation
A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy. Although novel oral anticoagulants alone may be effective in thrombus dissolution, the association of an antiplatelet drug may safely enhance this process.
Source: Journal of Cardiovascular Medicine - October 7, 2017 Category: Cardiology Tags: Images in cardiology Source Type: research

Dosing issues with non-vitamin  K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Arch Cardiovasc Dis. 2017 Oct 02;: Authors: Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N Abstract Non-vitamin K antagonist oral anticoagulants (NOACs) - dabigatran, rivaroxaban, apixaban and edoxaban - are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When prescribed incorrectly...
Source: Archives of Cardiovascular Diseases - October 2, 2017 Category: Cardiology Authors: Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N Tags: Arch Cardiovasc Dis Source Type: research

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We determined the effectiveness and associated r...
Source: BMC Cardiovascular Disorders - September 6, 2017 Category: Cardiology Authors: Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson and Alvaro Alonso Tags: Research article Source Type: research